Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin and gemcitabine with or without vandetanib for first-line advanced urothelial cancer in cisplatin-ineligible patients
2009-010140-33Phase 2Completed
- Sponsor
- Cardiff University
- Start
- Sep 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in transitional cell carcinoma (TCC) comparing Carboplatin + gemcitabine with Zactima + carboplatin + gemcitabine (2 arms). Primary endpoint: Progression-free survival. Started Sep 2009; status: completed.
02
Drugs
vandetanibcarboplatingemcitabine
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2009-010140-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010140-33.